Weber R - Search Results

1

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma.

Petrova V, Arkhypov I, Weber R, Groth C, Altevogt P, Utikal J, Umansky V. Petrova V, et al. Among authors: weber r. Int J Mol Sci. 2020 Mar 30;21(7):2367. doi: 10.3390/ijms21072367. Int J Mol Sci. 2020. PMID: 32235439 Free PMC article. Review.

2

Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.

Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V. Fleming V, et al. Among authors: weber r. Front Immunol. 2018 Mar 2;9:398. doi: 10.3389/fimmu.2018.00398. eCollection 2018. Front Immunol. 2018. PMID: 29552012 Free PMC article. Review.

3

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors.

Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V. Weber R, et al. Front Immunol. 2018 Jun 11;9:1310. doi: 10.3389/fimmu.2018.01310. eCollection 2018. Front Immunol. 2018. PMID: 29942309 Free PMC article. Review.

4

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.

Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J, Umansky V. Groth C, et al. Among authors: weber r. Br J Cancer. 2019 Jan;120(1):16-25. doi: 10.1038/s41416-018-0333-1. Epub 2018 Nov 9. Br J Cancer. 2019. PMID: 30413826 Free PMC article. Review.

5

Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling.

Fleming V, Hu X, Weller C, Weber R, Groth C, Riester Z, Hüser L, Sun Q, Nagibin V, Kirschning C, Bronte V, Utikal J, Altevogt P, Umansky V. Fleming V, et al. Among authors: weber r. Cancer Res. 2019 Sep 15;79(18):4715-4728. doi: 10.1158/0008-5472.CAN-19-0053. Epub 2019 Jul 23. Cancer Res. 2019. PMID: 31337655

6

Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors.

Simon SCS, Hu X, Panten J, Grees M, Renders S, Thomas D, Weber R, Schulze TJ, Utikal J, Umansky V. Simon SCS, et al. Among authors: weber r. Oncoimmunology. 2020 Feb 15;9(1):1727116. doi: 10.1080/2162402X.2020.1727116. eCollection 2020. Oncoimmunology. 2020. PMID: 32117594 Free PMC article.

7

Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles.

Arkhypov I, Lasser S, Petrova V, Weber R, Groth C, Utikal J, Altevogt P, Umansky V. Arkhypov I, et al. Among authors: weber r. Int J Mol Sci. 2020 Aug 31;21(17):6319. doi: 10.3390/ijms21176319. Int J Mol Sci. 2020. PMID: 32878277 Free PMC article. Review.

8

IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy.

Weber R, Groth C, Lasser S, Arkhypov I, Petrova V, Altevogt P, Utikal J, Umansky V. Weber R, et al. Cell Immunol. 2021 Jan;359:104254. doi: 10.1016/j.cellimm.2020.104254. Epub 2020 Nov 29. Cell Immunol. 2021. PMID: 33296753 Review.

9

Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study.

Gebhardt C, Simon SCS, Weber R, Gries M, Mun DH, Reinhard R, Holland-Letz T, Umansky V, Utikal J. Gebhardt C, et al. Among authors: weber r. Cell Immunol. 2021 Feb;360:104274. doi: 10.1016/j.cellimm.2020.104274. Epub 2020 Dec 28. Cell Immunol. 2021. PMID: 33383383

10

Tumor promoting capacity of polymorphonuclear myeloid-derived suppressor cells and their neutralization.

Groth C, Weber R, Lasser S, Özbay FG, Kurzay A, Petrova V, Altevogt P, Utikal J, Umansky V. Groth C, et al. Among authors: weber r. Int J Cancer. 2021 Nov 1;149(9):1628-1638. doi: 10.1002/ijc.33731. Epub 2021 Jul 17. Int J Cancer. 2021. PMID: 34224592 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,929 results

Search Page

Filters